TY - JOUR
T1 - Xanthomas and hyperlipidemias
AU - Parker, Frank
N1 - Funding Information:
iAtP,; §' The CME articles are made possible through an ed" '.,,,,0' ucational grant from Syntex Laboratories, Inc. From the Department of Dermatology, The Oregon Health Sciences University. Reprint requests to: Dr. Frank Parker, Department of Dermatology, The Oregon Health Sciences University, 3181 S.W, Sam Jackson Park Rd., Portland, OR 97201.
PY - 1985
Y1 - 1985
N2 - The ability to recognize diverse clinical forms of xanthomas, such as tuberous, planar, eruptive and tendinous, is important in the detection of underlying systemic disease. A variety of primary genetic disorders, as well as numerous secondary conditions such as diabetes, obstructive liver disease, thyroid disease, renal disease, and pancreatitis, can lead to hyperlipoproteinemia that results in the formation not only of xanthomas but also of life-threatening vascular atherosclerosis. An understanding of the pathogenesis of the underlying lipoprotein alterations provides a rational approach to therapy utilizing dietary manipulations and drugs. Such treatment is capable of correcting most disorders of lipid metabolism, and, if appropriate therapy is initiated at the first sign of xanthoma evolution, it may prevent progression of atherosclerosis, provide resolution of xanthomas, and in some instances prevent serious pancreatitis.
AB - The ability to recognize diverse clinical forms of xanthomas, such as tuberous, planar, eruptive and tendinous, is important in the detection of underlying systemic disease. A variety of primary genetic disorders, as well as numerous secondary conditions such as diabetes, obstructive liver disease, thyroid disease, renal disease, and pancreatitis, can lead to hyperlipoproteinemia that results in the formation not only of xanthomas but also of life-threatening vascular atherosclerosis. An understanding of the pathogenesis of the underlying lipoprotein alterations provides a rational approach to therapy utilizing dietary manipulations and drugs. Such treatment is capable of correcting most disorders of lipid metabolism, and, if appropriate therapy is initiated at the first sign of xanthoma evolution, it may prevent progression of atherosclerosis, provide resolution of xanthomas, and in some instances prevent serious pancreatitis.
KW - 3-hydroxy-3-methylglutaryl
KW - HDL
KW - HMG
KW - IDL
KW - LCAT
KW - LDL
KW - LPL
KW - PL
KW - TG
KW - VLDL
KW - high-density (or alpha) lipoprotein
KW - intermediate-density (or remnant) lipoprotein
KW - lecithin-cholesterol acyltransferase
KW - lipoprotein lipase
KW - low-density (or beta) lipoprotein
KW - phospholipid
KW - triglyceride
KW - very low-density (or prebeta) lipoprotein
UR - http://www.scopus.com/inward/record.url?scp=0021884702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021884702&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(85)70139-9
DO - 10.1016/S0190-9622(85)70139-9
M3 - Article
C2 - 4031142
AN - SCOPUS:0021884702
SN - 0190-9622
VL - 13
SP - 1
EP - 30
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -